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Abstract
Introduction:  Most  cancer  patients  are  treated  with  chemotherapy,  and  peripheral  neurop-
athy is  a  serious  and  common  clinical  problem  affecting  patients  undergoing  cancer  treatment.
However,  the  symptoms  are  subjective  and  underdiagnosed  by  health  professionals.  Thus,  it
becomes necessary  to  develop  self-report  instruments  to  overcome  this  limitation  and  improve
the patient’s  perception  about  his  medical  condition  or  treatment.
Objective:  Translate  and  culturally  adapt  the  Brazilian  version  of  the  Pain  Quality  Assessment
Scale, constituting  a  useful  tool  for  assessing  the  quality  of  neuropathic  pain  in  cancer  patients.
Method: The  procedure  followed  the  steps  of  translation,  back  translation,  analysis  of  Por-
tuguese and  English  versions  by  a  committee  of  judges,  and  pretest.  Pretest  was  conducted
with 30  cancer  patients  undergoing  chemotherapy  following  internationally  recommended  stan-
dards, and  the  ﬁnal  versions  were  compared  and  evaluated  by  a  committee  of  researchers  from
Brazil and  MAPI  Research  Trust,  the  scale’s  creators.
Results:  Versions  one  and  two  showed  100%  semantic  equivalence  with  the  original  version.
Back-translation  showed  difference  between  the  linguistic  translation  and  the  original  version.
After evaluation  by  the  committee  of  judges,  a  ﬂaw  was  found  in  the  empirical  equivalence
and idiomatic  equivalence.  In  pretest,  two  people  did  not  understand  the  item  12  of  the  scale,
without interfering  in  the  ﬁnal  elaboration.
Conclusion:  The  translated  and  culturally  adapted  instrument  is  now  presented  in  this  publica-
tion, and  currently  it  is  in  the  process  of  clinical  validation  in  Brazil.a  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights© 2014  Sociedade  Brasileir
reserved. Institution: Instituto Maranhense de Oncologia Aldenora Bello.
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Traduc¸ão  e  adaptac¸ão  transcultural  da  Pain  Quality  Assessment  Scale  (PQAS)  para  a
versão  brasileira
Resumo
Introduc¸ão:  A  maioria  dos  pacientes  com  câncer  são  tratados  com  quimioterápicos  e  a  neu-
ropatia periférica  é  um  problema  clínico  sério  e  comum  que  afeta  os  pacientes  em  tratamento
oncológico.  Entretanto,  tais  sintomas  são  subjetivos  sendo  subdiagnosticado  pelos  proﬁssionais
de saúde.  Assim,  torna-se  necessário  o  desenvolvimento  de  instrumentos  de  autorrelato  para
superar essa  limitac¸ão  e  melhorar  a  percepc¸ão  do  paciente  sobre  o  seu  tratamento  ou  condic¸ão
clínica.
Objetivo: Traduzir  e  adaptar  transculturalmente  a  versão  brasileira  do  Pain  Quality  Assessment
Scale (PQAS),  constituindo  em  um  instrumento  útil  de  avaliac¸ão  da  qualidade  da  dor  neuropática
em pacientes  com  câncer.
Método:  O  procedimento  seguiu  as  etapas  de  traduc¸ão,  retrotraduc¸ão,  análise  das  versões  por-
tuguês e  inglês  por  um  comitê  de  juízes  e  pré-teste.  O  pré-teste  foi  realizado  em  30  pacientes
com câncer  em  tratamento  quimioterápico  seguindo  normas  internacionalmente  recomen-
dadas, sendo  as  versões  ﬁnais  comparadas  e  avaliadas  por  comitê  de  pesquisadores  brasileiros
e da  MAPI  Research  Trust,  originadores  da  escala.
Resultados:  As  versões  um  e  dois  apresentaram  100%  de  equivalência  semântica  com  a  ver-
são original.  Na  retrotraduc¸ão  houve  diferenc¸as  na  traduc¸ão  linguística  com  a  versão  original.
Após a  avaliac¸ão  do  Comitê  de  Juízes,  foi  encontrada  uma  falha  na  equivalência  empírica  e  na
equivalência  idiomática.  No  pré-teste,  duas  pessoas  não  entenderam  o  item  12  da  escala,  sem
interferir  na  elaborac¸ão  ﬁnal  da  mesma.
Conclusão:  O  instrumento  agora  traduzido  e  adaptado  transculturalmente  é  apresentado  nessa
publicac¸ão e,  atualmente,  encontra-se  em  processo  de  validac¸ão  clínica  no  Brasil.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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yIntroduction
Painful  experiences  are  exactly  alike.  People  use  the  word
‘pain’  to  describe  a  wide  variety  of  sensations  and  expe-
riences  arising  from  various  etiologies  Although  the  pain
intensity  or  magnitude  is  the  most  evaluated  characteris-
tic  on  clinical  experience  and  scientiﬁc  research,  currently
we  know  that  people  can  feel  the  same  pain  intensity,  but
with  different  qualities.1
Most  cancer  patients  are  treated  with  chemother-
apy.  Bone  marrow  suppression  and  renal  and  neurologic
toxicity  are  the  most  common  adverse  events  seen
after  the  use  of  chemotherapeutic  agents  for  treat-
ing  malignancies  and  the  main  reasons  for  anticancer
treatment  discontinuation  or  changing  the  treatment  reg-
imen.  The  neurotoxicity,  involving  both  the  peripheral
and  the  central  nervous  system,  tends  to  occur  early
and  persist  even  with  the  chemotherapy  reduction  or
discontinuation.2--7
Currently,  the  interest  in  the  subjective  percep-
tions  of  patients  about  the  intensity  and  the  effects
of  chemotherapy-induced  peripheral  neuropathy  (CIPN)
increased,  and  several  self-report  instruments  are  being
developed  to  assess  the  patient’s  perception  of  his/her
treatment  or  medical  condition.4,6--11
c
oAmong  the  self-report  instruments  used  in  clinical
ractice  there  is  the  Pain  Quality  Assessment  Scale  (PQAS)
Fig.  1).  PQAS  is  nonspeciﬁc  for  CIPN,  but  derives  from  a
cale  called  Neurophatic  Pain  Scale  (NPS).  The  NPS  was
eveloped  to  assess  distinct  pain  qualities  associated  with
europathic  pain,  the  ﬁrst  instrument  speciﬁcally  designed
or  this  purpose.12 The  scale  includes  two  items  that
ssess  the  overall  dimensions  of  intensity  and  intolera-
le  pain,  plus  eight  items  in  which  speciﬁc  qualities  of
europathic  pain  are  described  as:  ‘sharp’,  ‘hot’,  ‘poorly
ocalized,  ‘cold’,  ‘sensitive  as  raw  wound’,  ‘itchy’,  ‘super-
cial’  and  ‘deep’.12 Later,  it  was  necessary  to  add  10
escriptors  related  to  the  quality  of  pain  (‘sensitive  as
 wound’,  ‘numbness’,  ‘shocks’,  ‘tingling’,  ‘radiating’,
pounding’,  ‘like  a toothache’,  ‘sting’,  ‘cramp-like’,  and
weight’  type)  increasing  the  NPS  content  validity  and  three
tems  related  to  the  temporality  of  pain  (‘constant  with
ntermittent  increases’,  ‘intermittent’,  or  ‘constant  with
uctuation’),  which  was  useful  to  evaluate  both  neuropathic
nd  non-neuropathic  pain;1,13--16 thus,  originating  the  PQAS.
lthough  useful,  this  scale  has  not  been  validated  for  Brazil
et.Thus,  the  aim  of  this  study  was  to  translate  and  cross-
ulturally  adapt  the  PQAS  into  Portuguese  of  Brazil  in
rder  to  provide  clinicians  and  researchers  with  a  tool
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Figure  1  Flowchart  showing  the  steps  of  translation  and  cross-cultural  adaptation  of  the  Pain  Quality  Assessment  Scale  (PQAS)  at
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i referral  hospital  for  cancer  in  Brazil.
or  assessing  the  quality  of  neuropathic  pain  in  patients
ndergoing  chemotherapy  in  a  cancer  referral  public  hos-
ital.
aterials and methods
QAS  comprises  20  items  of  global  assessment  of  pain  sever-
ty  and  its  inconveniences,  two  spatial  aspects  of  pain,  and
6  different  qualities  of  pain.  Although  the  items  have  sim-
lar  characteristics  with  more  than  one  measure,  their  best
bility  is  to  capture  the  qualities  or  domains  affected  by  the
ain  treatment.  Each  item  uses  a  verbal  numerical  scale,
n  which  0  =  no  pain  or  no  sensation  and  10  =  the  worst  pain
maginable.  As  mentioned  above,  pain  is  assessed  using  two
lobal  domains  (pain  severity  and  discomfort  caused  by  it),
wo  spatial  domains  (deep  or  surface)  and  16  quality  domains
sharp,  hot,  poorly  localized,  cold,  sensitive  as  raw  wound,
mosquito  bite’,  sting,  numbness,  shock,  tingling,  cramp,
adiating,  pounding,  ‘like  a  toothache’,  and  weight).  Addi-
ionally,  PQAS  also  has  an  item  that  assesses  the  temporal
attern  of  pain  (intermittent  without  pain  at  other  times,
inimal  pain  all  the  time  with  exacerbation  periods,  and
onstant  pain  that  does  not  change  very  much  from  one
oment  to  another).1,13--16
i
t
d
cPQAS  translation  and  adaptation  were  performed  fol-
owing  the  internationally  recommended  standards.17 PQAS
as  translated  into  Portuguese  by  two  Brazilians  who
re  ﬂuent  in  English  and  Portuguese,  which  generated
wo  independent  versions  (V1  and  V2).  These  two  ver-
ions  were  evaluated  by  the  Brazilian  researchers  who
eveloped  a  third  version  (V3).  The  third  version  was
hen  subjected  to  back-translation  into  English,  per-
ormed  by  a  physician  ﬂuent  in  Portuguese  and  English,
ho  was  unaware  of  the  original  instrument  and  the
ranslation  purpose,  which  produced  an  English  version
V4).17,18
The  equivalence  of  each  item  in  the  original  English
ersion,  in  the  English  version  resulting  from  the  back-
ranslation  (V4),  and  in  the  third  version  in  Portuguese
V1  +  V2  =  V3)  were  reviewed  by  an  expert  committee
ormed  by  a  multidisciplinary  team  (physician,  nurse,  psy-
hologist,  physiotherapist),  who  knew  the  topic  researched,
he  purpose  of  the  instrument,  and  the  concepts  to  be  ana-
yzed.  The  experts’  work  was  to  detect  possible  differences
n  the  translations,  compare  the  terms  and  words  together,
dentifying  whether  the  scale  items  were  related  or  not
o  the  concepts  measured  in  the  original  instrument.  The
escriptors  accepted  by  at  least  80%  of  the  experts  were
onsidered  as  having  an  appropriate  translation.  From  the
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Table  1  The  back-translation  process  for  PQAS.
Original  scale  Back-translated  scale
4/Dull.  Difﬁcult  was  to  locate
your  pain.
7/Like  a  bruise. Like  a  wound.
8/Like  poison  ivy.  Like  a  tingle.
9/Zapping.  Hooked.
13/Tight.  Gripping.
15/Pounding.  Pulsatile.
19/How  intense  is  your
surface  pain?
How  intense  is  your
shallow  pain?
20/I  have  variable  pain
(background  pain  all
the time,  but  also
moments  of  more  pain
or even  severe
breakthrough  pain  or
varying  types  of  pain).
I  have  variable  pain  or
even  with  moments  of
suddenly  severe  pain  or
different  levels  of
intensity  of  pain.
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between  the  terms,  only  in  item  12  two  people  did  not
choose  because  they  did  not  understand  the  scale  sense.
Table  2  Terms  chosen  for  Version  1  after  the  expert  com-
mittee  review.
Item  in  V1  Scale  Expert  committee  review
2  Worst  acute  pain  imaginable
3 No  burning
5 No  cold  sensation/worst  cold
sensation  imaginable  ‘freezing’
6 No  sensitive/the  most  sensitive
possible  (raw  skin)
7 No  sensitive/the  most  sensitive
possible  (wound-like)
8 No  itching
10 No  numbness/the  worst
numbness  sensation  imaginable
11 No  shocks/the  worst  sensation
of shocks  imaginable
13 No  cramp  sensation/the  worst
cramp  sensation  imaginable
14 No  irradiationTranslation  and  transcultural  adaptation  of  PQAS  
experts’  opinions,  the  ﬁnal  version  of  the  instrument  (V5)
was  developed.17,18
The  decisions  made  by  this  committee  were  based  on  the
equivalence  between  the  source  and  target  version  in  four
aspects:
a)  Semantic  equivalence: knowing  if  the  translated  words
have  the  same  meaning;  if  multiple  meanings  come  from
a  particular  item,  and  if  there  were  grammatical  difﬁ-
culties  in  translation.
b)  Idiomatic  equivalence: equivalent  expressions  were  for-
mulated  in  the  target  version,  avoiding  difﬁculties  in
translating  colloquialisms  and  idioms.
c)  Empirical  Equivalence: terms  in  the  questionnaire  were
replaced  by  similar  terms  which  are  used  in  our  culture
of  origin,  seeking  to  capture  daily  life  experiences.
d)  Conceptual  equivalence: it  was  observed  if  the  words
had  different  meanings  across  cultures,  replacing  the
inadequate  terms.17--19
Consensus  was  reached  on  all  items,  with  the  presence
of  all  translators  on  the  committee,  providing  a  good  under-
standing  immediately.17,18
After  choosing  the  ﬁnal  version  (V5),  the  pre-test  was
conducted  with  30  patients  undergoing  chemotherapy  at
a  referral  hospital  for  oncology  in  Brazil  after  signing  the
informed  consent.  They  completed  the  questionnaire,  were
asked  what  they  thought  of  each  item,  and  choose  the  best
answer.17,18
Semantic  equivalence  was  performed  under  the  coordi-
nation  of  the  MAPI  Research  Trust,  Lyon,  France,  researchers
who  drafted  the  original  PQAS  with  the  main  investigator
participation.
Results
The  ﬁnal  Brazilian  version  of  the  PQAS  resulted  from  the
back-translation  and  experts’  review  and  is  being  submitted
to  an  evaluation  of  its  psychometric  properties  in  an  ongoing
study  by  the  pain  team  of  the  University  Hospital,  a  referral
center  in  Brazil.
During  the  preparation  of  the  V1  and  V2  versions,  we
observed  100%  semantic  agreement  among  translators.  In
item  4,  in  which  we  asked  how  dull  your  pain  feels?----the
word  ‘‘dull’’  was  translated  as  ‘‘indeﬁnida’’  (undeﬁned)  on
these  two  versions,  which  did  not  persist  after  the  experts
review.
In  back-translation,  we  saw  differences  in  language  trans-
lation  with  the  original  version.  In  item  1,  the  word  ‘intense’
in  the  original  was  back-translated  as  ‘severe’.  In  item  2,
‘like  a  spike’  was  replaced  by  ‘like  a  needle’  and  ‘the  most
sharp’  by  ‘the  most  prickling’.  All  other  items  are  summa-
rized  in  Table  1.
During  the  expert  committee  evaluation,  there  were  no
differences  in  semantic  and  conceptual  equivalence.  As  pre-
viously  mentioned,  the  word  ‘dull’  in  item  4  was  translated
as  ‘undeﬁned’  in  versions  1  and  2.  However,  such  expression
was  judged  as  having  little  information  about  the  patient’s
painful  feature  in  our  native  language,  which  was  identiﬁed
as  a  gap  in  empirical  equivalence.  Thus,  it  was  replaced  byPQAS, Pain Quality Assessment Scale.
he  term  ‘poorly  localized’,  best  exemplifying  this  quality
f  pain  in  our  regional  population.
The  experts  also  identiﬁed  colloquialisms  and  idioms  that
ould  interfere  with  the  correct  description  of  the  quality
f  pain  in  our  population,  such  as  in  item  1  with  ‘nenhuma
or’  (no  pain  at  all)  in  V1  and  ‘sem  dor’  (no  pain)  in  V2,  the
erm  ‘sem  dor’  (no  pain)  was  chosen  for  the  ﬁnal  version.
his  fact  results  in  a  change  in  idiomatic  equivalence.  After
ompletion  of  this  phase,  version  5  of  the  instrument  was
enerated.  Tables  2  and  3  show  the  other  terms.
During  the  pre-test,  in  which  patients  are  asked  to  choose16 No  soreness/the  worst
sensation  of  soreness
imaginable
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Table  3  Terms  chosen  in  Version  2  after  the  expert  committee  review.
Item  in  V2
Scale
Expert  committee  review  Item  in  V2
Scale
Expert  committee  review
1  The  most  severe  pain  you  have  ever
experienced
14  The  worst  pain  irradiation  imaginable
(spread)
2 No  sharp  pain/the  worst  sensation  of
sharp  pain  ever  felt  (like  a  knife)
15  No  pounding  pain/the  worst  sensation
of pounding  pain  imaginable
3 The  worst  hot  pain  ever  felt  (burning)  17  No  weight-like  pain/the  worst
sensation  of  weight-like  pain  (very
strong)
4 No  pain/the  worst  sensation  of
‘‘poorly  localized  pain’’  imaginable
18  No  bothering/the  most  intolerable
sensation  of  pain  imaginable
8 The  worst  itching  sensation
imaginable  (like  a  mosquito  bite)
19  No  deep  pain/the  deepest  pain
imaginable;  No  surface  pain/severe
pain  on  the  body  surface
9 No  stinging  pain/the  worst  stinging
pain  ever  felt
20  All  scale  items  were  chosen
12 No  tingling/the  worst  tingling
sensation  imaginable
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An  other  terms,  100%  of  patients  reported  understanding  the
tems  chosen  without  any  difﬁculty.
Despite  this  small  difference,  the  originators  of  the  scale
ecided  that  there  was  semantic  concordance  between  the
wo  translations,  and  that  the  validation  process  could  be
tarted.
iscussion
he  main  objective  of  this  study  was  achieved  with  the  suc-
essful  translation  and  cross-cultural  adaptation  of  the  PQAS
nto  Portuguese.
Among  the  various  adverse  events  resulting  from
hemotherapy,  CIPN  remains  the  diagnosis  in  later  stages
f  the  disease  with  moderate  to  severe  symptoms  of  sen-
ory  and/or  motor  neuropathy,  when  the  quality  of  life  of
hese  individuals  is  already  compromised  both  physically  and
motionally.  Thus,  we  chose  to  validate  the  PQAS  in  this
opulation  of  patients  who  often  report  tingling,  stinging  or
urning,  numbness,  pinpricks  and  bilateral  shock-like  sen-
ations  in  hands  and  feet  as  symptoms  resulting  from  CIPN
n  early  stages  of  the  disease.  Furthermore,  the  absence
f  a  gold  standard  instrument  to  identify  this  disease  fur-
her  hinders  any  possibility  of  prevention  and  appropriate
reatment.10
Other  studies,  which  compared  the  effects  of  differ-
nt  pain  treatments  for  patients  with  similar  qualities  of
ain,  reported  effects  both  similar  and  different  for  cer-
ain  qualities,  depending  on  the  studied  population  and
reatment.1 One  study  compared  the  effects  of  5%  lidocaine
atch  with  corticoid  injection  alone  in  carpal  tunnel  syn-
rome  (CTS).  The  results  showed  a  decrease  in  tingling,
umbness,  unpleasant  sensation,  deep  ache,  electric-like,
ntense,  superﬁcial,  sharp,  burning,  and  unpleasant  sensa-
ions  in  both  treatments,  with  greater  effects  on  pounding
nd  numbness  with  the  lidocaine  patch9.  In  the  group
f  neuropathic  pain  patients  with  postherpetic  neuralgia
t
a
i
wnd  diabetic  neuropathy,  a  combination  of  oxycodone  and
regabalin  showed  signiﬁcant  improvement  in  freezing  cold
ain,  although  the  combination  of  pregabalin  and  placebo
ad  improved  burning  and  sharp  pain.1 The  results  of
hese  studies  suggest  the  efﬁcacy  of  various  pharmacolog-
cal  treatments  for  certain  qualities  of  pain  in  patients
ith  speciﬁc  diagnoses.  Thus,  the  translation  and  cross-
ultural  adaptation  of  PQAs  and  its  subsequent  validation
ill  provide  a  useful  tool  for  this  purpose  in  our  population.
The  development  of  the  V1  and  V2  versions  was  not
ifﬁcult.  However,  the  physician  who  performed  the  back-
ranslation  reported  difﬁculty  to  ﬁnish  it,  as  he  represents
 different  specialty  from  the  researched  topic,  in  addition
o  the  fact  that  many  terms  that  refer  to  painful  conditions
re  not  easy  to  express  exactly  the  quality  of  the  pain  the
atient  feels.  This  generated  more  reliability  to  this  stage
f  the  research,  as  the  back-translated  version  was  deemed
ompatible  by  the  originators  of  the  scale.
The  pretest  phase  is  necessary  for  the  completion  of  the
ranslation  and  cultural  adaptation  process  of  the  scales.
uring  the  study,  it  was  necessary  to  give  more  extensive
xplanations  of  some  terms  due  to  the  low  educational  level
f  the  population  surveyed.  In  a  study  conducted  in  Japan,18
atients  reported  problems  regarding  the  understanding  of
tems,  some  being  considered  irrelevant,  diverging  from  this
tudy  where  such  action  was  not  necessary.  There  was  no
roblem  with  the  scale  creators’  authorization  to  start  the
rocess  of  its  translation,  cross-cultural  adaptation,  and
alidation.
During  data  collection,  the  questionnaire  was  completed
hrough  an  interview  via  clinician/researcher  and  patient
sing  only  pencil  and  paper.  Patients  took  about  15  minutes
n  average  to  answer  the  questionnaire  for  the  ﬁrst  time.
t  other  times,  this  time  was  longer.  After  realizing  that
his  could  be  a  complicating  factor  for  the  questionnaire
pplication  in  the  routine  of  crowded  ofﬁces,  a  small  train-
ng  among  researchers  was  conducted.  Thus,  the  interview
as  conducted  with  more  simple  and  easy  to  understand
a
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terms,  as  most  patients  had  a  more  elementary  level  of
education.  It  was  then  possible  to  reduce  the  interview
time  to  8--10  minutes  without  compromising  the  visit  time
and  achieving  patient  satisfaction.  However,  it  is  known
that  patients  have  difﬁculty  expressing  painful  symptoms,
especially  when  they  are  associated  with  CIPN.10 This  may
explain  the  difﬁculty  faced  by  patients  to  complete  the
questionnaire.
Although  there  is  no  gold  standard  process  to  be  strictly
followed  by  all  researchers  in  order  to  perform  a  transla-
tion  and  cross-cultural  adaptation,  three  steps  are  essential:
translation/back-translation,  expert  committee  review,  and
pretest.  All  three  steps  in  this  study  were  rigorously
monitored.18
C
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Thus,  the  Brazilian  version  of  PQAS  is  now  translated
nd  culturally  adapted  and,  after  its  validation  (currently  in
rogress  by  the  Pain  Research  Group  at  the  University  Hos-
ital,  a  referral  center  in  Brazil),  it  will  certainly  be  a  useful
ool  for  clinicians  and  researchers  to  evaluate  the  signs  and
ymptoms  of  different  qualities  of  pain,  neuropathic  or  not,
elping  to  elucidate  the  painful  mechanism,  evaluate  the
ffectiveness  of  treatment  of  different  diseases,  and  espe-
ially  in  the  early  detection  of  sensory  symptoms  in  patients
t  risk  of  developing  more  serious  stages  of  CIPN.onﬂicts of interest
he  authors  declare  no  conﬂicts  of  interest.
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nnex. Portuguese ﬁnal version of the Pain
uality Assessment Scale (PQAS)
101Translation  and  transcultural  adaptation  of  PQAS  
1 A.B.  Carvalho  et  al.02  
103
1
1
1
1
1
1Translation  and  transcultural  adaptation  of  PQAS  
References
1. Jensen MP, Galer BS, Gammaitomi AR, et al. The Pain Quality
Assessment Scale (PQAS) and Revised Pain Quality Assessment
Scale (PQAS-R): Manual and User Guide; 2010. Mapi Research
Trust website (http://www.mapi-trust.org).
2. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral
neuropathy. J Neurol. 2002;249:9--17 [review].
3. Stillman M, Cata JP. Management of chemotherapy-induced
peripheral neuropathy. Curr Pain Headache Rep. 2006;10:
279--87.
4. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral
neurotoxicity. Nat Rev Neurol. 2010;6:657--66.
5. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy.
J Peripher Nerv Syst. 2008;13:27--46 [review].
6. Smith EM, Cohen JA, Pett MA, et al. The validity of neurop-
athy and neuropathic pain measures in patients with cancer
receiving taxanes and platinums. Oncol Nurs Forum. 2011;38:
133--42.
7. Naleschinski D, Baron R, Miaskowski C. Identiﬁcation and treat-
ment of neuropathic pain in patients with cancer. Pain Clin
Updates. 2012;XX.8. Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-
induced peripheral neurotoxicity assessment: a critical revision
of the currently available tools. Eur J Cancer. 2010;46:
479--94.
19. Ferreira KA, Teixeira MJ, Mendonza TR, et al. Validation of brief
pain inventory to Brazilian patients with pain. Support Care
Cancer. 2011;19:505--11.
0. Sasane M, Tencer T, French A, et al. Patient-reported outcomes
in chemotherapy-induced peripheral neuropathy: a review. J
Support Oncol. 2010;8:E15--21.
1. Ferreira KASL, William NW Jr, Mendonza TRK, et al. Traduc¸ão
para a Língua Portuguesa do M.D. Anderson Symptom Inven-
tory -- head and neck module (MDASI-H&N). Rev Bras Cir Cabec¸a
Pescoc¸o. 2008;37:109--13.
2. Galer BS, Jensen MP. Development and preliminary validation
of a pain measure speciﬁc to neuropathic pain: the neuropathic
pain scale. Neurology. 1997;48:332--8.
3. Jensen MP, Gammaitoni AR, Olaleye DO, et al. The pain quality
assessment scale: assessment of pain quality in carpal tunnel
syndrome. J Pain. 2006;11:823--32.
4. Victor TW, Jensen MP, Gammaitoni AR, et al. The dimensions
of pain quality: factor analysis of the pain quality assessment
scale. Clin J Pain. 2008;24:550--5.
5. Waterman C, Victor TW, Jensen MP, et al. The assessment
of pain quality: an item response theory analysis. J Pain.
2010;11:273--9.6. Wampler MA, Miaskowski C, Hamel K, et al. The modiﬁed total
neuropathy score: a clinically feasible and valid measure of
taxane-induced peripheral neuropathy in women breast cancer.
J Support Oncol. 2006;4:W9--16.
11
104  
7. Beaton DE, Bombardier C, Guillemin F, et al. Guidelines for the
process of cross-cultural adaptation of self-report measures.
Spine. 2000;25:3186--91.
8. Fumimoto H, Kobayashi K, Chang C-HE, et al. Cross-cultural vali-
dation of an international questionnaire, the general measure
1A.B.  Carvalho  et  al.
of the functional assessment of cancer therapy scale (FACT-G),
for Japanese. Qual Life Res. 2001;10:701--9.
9. Aaronson N, Alonso J, Burnam A, et al. Assessing health status
and quality-of-life instruments: attributes and review criteria.
Qual Life Res. 2002;11:193--205.
